Screening of migrants for tuberculosis identifies patients with multidrug-resistant tuberculosis but is not sufficient by Helbling, P. et al.
lable at ScienceDirect
Clinical Microbiology and Infection 24 (2018) 918e919Contents lists avaiClinical Microbiology and Infection
journal homepage: www.cl in icalmicrobiologyandinfect ion.comLetter to the Editor
Screening of migrants for tuberculosis identifies patients with multidrug-resistant
















































Fig. 1. Entry screening of multidrug-resistant tuberculosis cases of a cluster of patientsDear Sir,
An analysis of a cluster of 29 migrants with multidrug-resistant
(MDR) tuberculosis (TB) strains with an identical whole genome
sequencing pattern (difference of maximally one single nucleotide
polymorphism) identified in seven European countries in
2016e2017 has been published in Lancet Infectious Diseases [1].
The investigation of this cluster led to the conclusion that cases
are most likely linked to a larger Mycobacterium tuberculosis clone
circulating in northern Somalia/Djibouti, and that transmission
likely occurred prior to arrival in Europe [1,2]. Since most European
countries have entry screening [3] for TB for migrants, this raises the
question whether entry screening identified the cases and if not,
why not. Because this was not addressed in the publication by
Walker et al., we have assessed it in a short survey of the European
Centre for Disease Prevention and Control (ECDC)with the countries
involved. Information was collected on procedures for screening of
migrants, cases in the cluster subjected to screening, cases identified
by screening and cases in the cluster not identified by screening but
diagnosed later, usually due to symptoms.
After the data collection by Walker et al. was closed, Germany
identified five additional patients and Italy identified two cases so
that the total number of clustered patients was 36 as of end of
November 2017. Germany could provide information on screening
for 19/19 patients, Switzerland for 8/8, Italy for 2/2, Finland for 1/1,
Sweden for 1/1, and France for 1/2. There was no response from
Austria (0/2) and UK (0/1). In total, screening status was known for
32/36 patients.
Twenty-seven of the 32 patients (84%) were known to have un-
dergone screening, 19 in Germany and eight in Switzerland (Fig. 1).
The patient in Sweden had presented with symptoms before entry
screening. The patients in Italy and the one in France were not
screened and the patient in Finland was not screened due to the
large number of concurrent arrivals.
Countries had different screening practices. In Germany,
screening by chest X-ray is mandatory for asylum seekers
15 years of age (if not pregnant) before they are accommodated
in a community shelter. For asylum seekers <15 years of age, a tu-
berculin skin test (TST) or interferon gamma release assay (IGRA) is
recommended and, if positive, further investigation for active TB.
Switzerland implements mandatory symptom screening by inter-
view within 5 days after a request for asylum. Finland and Sweden
offer voluntary screening to migrants from countries with a high
incidence of TB that includes an interview. In Sweden screeninghttps://doi.org/10.1016/j.cmi.2018.03.015
1198-743X/© 2018 The Authors. Published by Elsevier Ltd on behalf of European Society
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).is performed by IGRA or TST, followed by chest X-ray in case of a
positive TST or IGRA and in Finland migrants are screened by chest
X-ray. In France, screening is not mandatory at entry but highly rec-
ommended for asylum seekers originating from high incidence
countries. Italy does not implement systematic screening of mi-
grants for TB at entry at national level, but screening is performed
in some regions.originating from the Horn of Africa defined by whole genome sequencing.
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15e25 years) 13 (48%) (10/19 in Germany and 3/8 in Switzerland)
were identified as a result of the screening and 14 (52%) were not
identified (Fig. 1). Of the five cases (three pulmonary TB, one pleural
TB, one lymphatic intrathoracic TB) not identified in Switzerland by
symptom screening (followed by chest X-ray if TB is suspected),
one did not report any symptoms, three (including the two extrapul-
monary TB cases) reported symptoms not deemed sufficient for
referral to a medical consultation including a chest X-ray, and one
referral resulted in a chest X-ray thatwas deemednormal. Nine cases
(seven pulmonary TB, one pleural TB, one bone TB) were not identi-
fied by screening inGermany. Onepulmonary TB case did not receive
a chest X-ray because the patientwas pregnant and under treatment
for other disease symptoms. None of the nine cases reported symp-
toms related to TB. Of the 32 cases for whom screening status was
known, 17 cases (53%) were identified when symptoms led to inves-
tigations days tomonths after screening or after entry to the country.
This analysis shows that, even though three-quarters of patients
were known to have undergone a screening procedure after
entering the host country, only approximately half of those
screened were diagnosed as a result of screening. Patients not iden-
tified by screening may have developed radiological abnormalities
or symptoms weeks or months after screening and may thus not
have been detectable at screening for active disease. Also, sensi-
tivity for identifying TB of the screening methods used varies; the
Swiss screening system has a sensitivity known to be lower than
systems using chest X-ray [4].
We conclude that systematic TB screening of migrants at country
entry can identify TB disease, which supports the objective of pre-
venting TB transmission by timely detection and treatment.
Screening at entry only identifies prevalent active TB. Persons
infected with TB but without clinical and/or radiological signs will
not be detected by entry screening for active TB but can develop TB
in themonthsoryears followingmigration. Screeningandpreventive
treatment for latent TB infectionmay prevent the development of TB
but is very unlikely to prevent the development ofMDR-TB [5]. In any
case, it is of utmost importance toprovide easy/barrier-free access for
migrants to thehealth system in thehost countries and forhealthcare
workers to have a high index of suspicion for TB in patients origi-
nating from countries with high TB incidence to ensure early detec-
tion and treatment of cases and avoid further spread [6].
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